BD Rx Inc., a wholly-owned subsidiary of Becton, Dickinson and Co., has received its third approval from the FDA for a drug to be offered in its new BD Simplist line of ready-to-administer prefilled generic injectables. The antiemetic Ondansetron Injection, USP 4mg/2mL (2mg/mL) is used to prevent postoperative nausea and vomiting, and is currently on the FDA drug shortage list due to demand increases and supply issues for other manufacturers.
“We’re proud to be expanding our BD Simplist products with a drug like Ondansetron Injection, USP which is in high demand among clinicians and fills a need for an intervention that can be administered quickly,” said Mark Sebree, president, BD Rx. “As we establish our product line with a third drug approval, we are seeing even further indication of the positive response to our new BD Simplist prefilled injectables especially among repeat customers.”
In March, BD announced that it would be manufacturing generic pharmaceutical products for the first time through BD Rx, which also manufactures Metoclopramide Injection, USP and Diphenhydramine Hydrochloride Injection, USP within the BD Simplist prefilled injectables line of products.
BD Rx plans to launch 20 to 30 drugs in its BD Simplist line of products during the next few years and is targeting generic injectables in doses most commonly used in both the hospital and surgical center settings.